ALZpath Inc.

Thank you, Cognition Therapeutics, Inc., for your recognition! We’re honored to see the ALZpath #pTau217 blood test recognized as one of the TIME Best Inventions of 2024?and thrilled to witness its impact in real-world trials like yours. Here’s to continued progress in Alzheimer’s care and more breakthroughs to come!

The ALZpath Inc. team is excited to be at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference in Madrid, Spain! This global event brings together leading researchers, clinicians, and industry experts to advance the discovery of treatments for Alzheimer’s disease. We’re here to support and present advancements in Alzheimer’s diagnostics, particularly with our pTau217 assay. ? Don’t miss the upcoming presentations featuring our?proprietary?#pTau217 assay: ???Plasma pTau217 Alone Is Not Enough for Staging Alzheimer’s Disease? Date: October 31 | Time: 12:15-12:30??(GMT+1) Presented by J.D. Doecke and collaborators ? ???Comparison of One-Step and Two-Step Workflows Using pTau217?? Date: October 31 | Time: 15:40-15:55?(GMT+1) Presented by J. Ahn and collaborators ? ???Differential Roles of Alzheimer’s Disease Plasma Biomarkers? Date: November 1 | Time: 14:55-15:10?(GMT+1) Presented by H. Jang and collaborators ???The Role of pTau217 in Integrated Amyloid and Tau Staging: Implications for Cognitive Trajectories in Alzheimer’s Disease Date: November 1 | Time: 08:30-08:45 (GMT+1) Presented by D. Shin and collaborators ???Timing of Changes in Alzheimer’s Disease Plasma Biomarkers Using Amyloid and Tau PET Clocks Date: November 1 | Time: 08:45-09:00 (GMT+1) Presented by M. Milà-Alomà and collaborators Posters featuring ALZPath pTau217 assay: - P104: Plasma pTau181 and pTau217 Similarly Predict Asymptomatic Amyloid Accumulation - P114: Plasma pTau217 as a Screening Tool for Future AD Neuropathology in Dementia-Free Individuals - P119: Plasma pTau and Amyloid Biomarkers’ Discrimination Accuracy in Alzheimer’s Disease - P123: Is Serum pTau217 a Viable Biomarker for Alzheimer’s Disease? - P124: A Two-Stage Approach to Risk Stratification in Early-Stage Alzheimer’s Disease - P133: Preliminary Evaluation of Plasma ALZpath pTau217 in a Diverse Cohort - LP060: Plasma pTau217, PET, and Cognition in an African American Sample (AA-FAIM Study) - LP072: Clinical Biomarker Scoring System for Anti-Amyloid Clinical Trials We’re proud to support innovative research to make Alzheimer’s diagnostics more accessible and reliable. Stay tuned for updates from #CTAD24!?

TIME’s Best Inventions of 2024 list is out now, and ALZpath is so excited for the ALZpath pTau217 test to be a part of it! #TIMEBestInventionsToday ALZpath Inc. announced that it has been honored in TIME's annual Best Inventions list, which features 200 extraordinary innovations changing our lives. The ALZpath proprietary pTau217 antibody was recognized in the medical care category for its ability to accurately diagnose Alzheimer's disease. ?? Read the full press release here:?https://lnkd.in/dZihrxQz Alzheimer's Association? Dementia Alliance International (DAI) UsAgainstAlzheimer's

ALZpath Inc. is excited to announce our attendance at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) conference in Madrid, Spain, from October 29 – November 1, 2024! This global event brings together leading researchers, clinicians, and industry experts to advance the discovery of treatments for Alzheimer’s disease. At ALZpath, we are committed to democratizing access to our pTau217 antibody and accelerating the development of innovative diagnostics and treatments. Join us in Madrid as we work together to transform Alzheimer’s research and improve patient outcomes. To connect with us or schedule a meeting, please contact our Chief Business Officer, Jacob Hunter, at?[email protected]. We can't wait to meet you at CTAD 2024! #CTAD2024 #CTAD24 #AlzheimersResearch #ALZpath #ClinicalTrials #pTau217

Today, on?World Alzheimer's Day, we join the global community in raising awareness and taking action against Alzheimer's and dementia. September is World Alzheimer’s Month, and this year’s theme,?Time to Act on Dementia, Time to Act on Alzheimer’s?by Alzheimer's Disease International, calls us to address the stigma and misconceptions around this condition. According to Alzheimer's Disease International, 75% of people living with dementia remain undiagnosed, highlighting the need for greater awareness and early detection efforts. At ALZpath, we are proud to contribute to this mission with our groundbreaking work in Alzheimer’s research. Our #pTau217 antibody empowers researchers and clinicians to accelerate the discovery of new treatments and improve patient care. We are committed to driving progress toward early detection and effective therapies. As we observe World Alzheimer’s Month, we stand in solidarity with those affected and remain dedicated to advancing Alzheimer’s research. Together, we can make a real impact and change the narrative surrounding Alzheimer’s disease. #WorldAlzheimersDay #WorldAlzMonth #TimeToActOnAlzheimers #AlzheimersAwareness #ALZpath #Research #Innovation #EndAlzheimers

"The side effects are real, but the drug can buy a person invaluable months or years to spend with loved ones before dementia sets in." – Henrik Zetterberg, MD, PhD, Distinguished Scientific Advisor to ALZpath ? On July 25, the European Medicines Agency (EMA) made the decision not to approve lecanemab, a drug that has been shown to slow the progression of cognitive decline in individuals with early-stage Alzheimer’s disease. ? In his recent Nature Portfolio article, Dr. Zetterberg emphasizes the importance of involving experienced scientists in regulatory decisions to ensure that innovative treatments reach patients safely and effectively.? ? Read the full article in Nature:?https://lnkd.in/ghb5BpTC ? #Alzheimers #Lecanemab #ALZpath #PatientCare #Neuroscience #AlzheimersResearch ?

The burden of Alzheimer's disease and related dementias may seem daunting.?However, we are pleased to have thought leaders and Health Moonshot Community partners like StartUp Health who are in this fight with us. In a recent interview, our CEO, Chad Holland, shared some perspective on how ALZpath is purpose built to bring p-Tau217 testing to dramatically more of the patients that need it. However, whether it be through partnerships, like the one we recently signed with Roche, or further innovations guided by our outstanding founder team, ALZpath is not going to limit itself to p-tau217. "We're not just going to be a p-tau217 company going forward", says Holland.?"I think we're just at this early part of the convergence of neuroscience and medicine and drug development". ???Find out more about ALZpath's origins, current on market success and future plans by visiting?www.ALZpath.bio ???Read the full story?by StartUp Health here:?https://lnkd.in/g7WjpgAs #pTau217 #Alzheimers #HealthCareInnovation #Diagnostics #Biotechnology #BrainHealth #ALZpath Alzheimer's Association?, Alzheimer's Society, Alzheimer's Foundation of America, Dementia Alliance International, UsAgainstAlzheimer's, Alzheimer's Research UK, Cure Alzheimer's Fund, BrightFocus Foundation

ALZpath Inc. is on a mission to revolutionize Alzheimer’s disease diagnostics, and we’re looking for a Director/Sr. Director of Program & Project Management to help us get there. If you are a strategic thinker with exceptional leadership skills, this role offers the opportunity to drive high-impact projects and collaborate closely with our CEO and senior leadership team. What You’ll Do: - Lead the planning, execution, and monitoring of key programs and projects - Collaborate with senior leadership to develop and execute strategic goals - Oversee cross-functional initiatives and resource allocation across teams - Drive process improvements to support our rapid growth - Build strong relationships with internal teams and external partners - Establish KPIs to assess program performance and deliver key results - Provide leadership and mentorship as our Program & Project Management team grows What We’re Looking For: - 12+ years of experience in project/program management, preferably within biotechnology or life sciences - Strong strategic planning and execution skills - Proven ability to manage multiple high-priority initiatives in a fast-paced environment - Excellent communication, problem-solving, and leadership abilities - PMP or similar certification is a plus ??View the full job description on our website: www.alzpath.bio/careers #Hiring #BiotechJobs #ProjectManagement #ProgramManagement #AlzheimersDisease #ALZpath #ptau217

We are pleased that Longevity.Technology is amplifying the message of bringing accurate accurate and minimally invasive testing at scale to the Alzheimer's patients that need it. Our innovative pTau217 blood test, recently featured in their article "Are blood tests the new standard for Alzheimer’s diagnosis?", is setting a new standard in Alzheimer’s diagnostics. With up to 97% accuracy in detecting biomarkers, this test is not only highly sensitive but also scalable, enabling earlier diagnosis for millions of patients. As our CEO, Chad Holland , emphasized, "I think we now understand enough to make some really effective treatments happen. For those treatments to reach patients, you first have to formally diagnose them with Alzheimer’s in order for them to qualify for the therapy." Our test ensures that those who need diagnosis are identified sooner, paving the way for timely and effective treatment. Through strategic partnerships with industry leaders like Roche Diagnostics USA and Beckman Coulter Diagnostics, we’re expanding access to this critical diagnostic tool on a global scale. Our mission is clear: democratizing access to Alzheimer’s diagnostics and ensuring that every patient has the opportunity for timely care. ??Read the full Longevity Technology article here:?https://lnkd.in/gd48dTdG ??Learn more about the innovations at ALZpath by visiting our site:?www.alzpath.bio #pTau217 #Alzheimers #HealthcareInnovation #Diagnostics #Biotechnology #LongevityTechnology #ALZpath

Our ALZpath pTau217 antibody was recently featured in Medical Device Network. Genova Diagnostics, in partnership with Neurocode Labs, Inc., has launched a new Alzheimer’s Assessment blood test that utilizes the pTau217 biomarker for early detection of Alzheimer’s disease—before the onset of clinical symptoms. ? This innovative test represents a significant step forward in making Alzheimer’s diagnostics more accessible, allowing for earlier intervention and improved management of the disease. We're proud to be a part of this crucial development, contributing our proprietary #pTau217 antibody to help revolutionize how Alzheimer's is detected and managed. ? The growing acceptance of Tau biomarkers in blood for Alzheimer’s screening is a testament to the dedication and innovation within the field, and we're honored to see our technology playing a pivotal role in this evolution. ? Stay tuned for more updates as we continue our mission to democratize access to life-changing diagnostics and improve patient care globally. ??Interested in learning more??Read the full article here:?https://lnkd.in/dVyWxw6y ??Want to learn more about ALZpath? Visit our website to discover how we’re advancing Alzheimer’s research and enhancing patient care:?www.alzpath.bio ? #ALZpath #AlzheimersDisease #pTau217 #EarlyDetection #Neurocode #BiotechInnovation? ?